Global Real‐World Outcomes of Olaparib in Metastatic Castration‐Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70679 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Lorena Incorvaia und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Palermo, I…. Hauptthemen laut MEDLINE: Piperazines, Phthalazines, Prostatic Neoplasms, Castration-Resistant, Recombinational DNA Repair. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Evidence to guide the treatment for patients with metastatic castration‐resistant prostate cancer (mCRPC) and Homologous Recombination Repair (HRR) gene alterations outside of clinical trials remains limited. This was an observational, cohort study, including mCRPC patients with tumor harboring HRR alterations, progressed on a prior androgen receptor pathway inhibitor, and treated with olaparib monotherapy from January 1, 2020, to April 30, 2025. Primary objectives were time on treatment (ToT) and overall survival (OS). Secondary objective was to explore the role of gene and type and location of pathogenic variant (PVs) as potential molecular predictors of olaparib benefit. We included 201 patients in the analysis. No significant differences in OS across distinct HRR gene subgroups were observed (median OS BRCA1 / 2 vs. non‐ BRCA HRR: 16.3 months [95% CI, 13.0–69.6] vs. 14.2 [95% CI, 12.0–22.9; p = 0.681]). Primary refractoriness to olaparib occurred in 36 (18%) patients and was associated with poor survival (1 year‐OS rate of primary vs. non‐primary refractory: 20% vs. 77%; p < 0.001). The 1 year‐ToT rate of BRCA1 versus BRCA2 was 23% versus 39%, respectively ( p = 0.021). Frameshift PVs in the BRCA2 gene were a prognostic factor for shorter OS. Differences in OS according to the PV location in the BRCA2 functional domains were also significant. Olaparib demonstrated clinical activity in this global, real world, population of mCRPC patients with HRR‐altered tumors. Accurately detecting the multitude of variables associated with BRCA genetic variants represents a key area of research potentially affecting the patient's clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Palermo, Italy.
- Department of Sciences and Medical-Surgical Biotechnologies, Policlinico Umberto I, University of Rome, Rome, Italy.
- Department of Internal Medicine, Hematology/Oncology, Ochsner Medical Center, New Orleans, Louisiana, USA.
- Oncology 3 Unit, Istituto Oncologico Veneto - IOV IRCCS, Padova, Italy.
- Clinical Oncology, Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia.
- Clinical Oncology Unit, Careggi University Hospital, Florence, Italy.
ORCID-Profile: Lorena Incorvaia, Lorenzo Antonuzzo, Deniz Tural, Brigida Anna Maiorano, Vincenza Conteduca, Yüksel Ürün, Fernando Sabino Marques Monteiro
Zitieren
APA
Incorvaia, L., Santini, D., Matrana, M. R., Maruzzo, M., Kopp, R. M., Antonuzzo, L., Bracarda, S., Tural, D., Procopio, G., Bourlon, M. T., Caffo, O., Zapata Laguado, M. I., Di Maio, M., Maiorano, B. A., Conteduca, V., Rossetti, S., Lipari, H., Büttner, T., Rizzo, M., …, & Taha, T. (2026). Global Real‐World Outcomes of Olaparib in Metastatic Castration‐Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations. International Journal of Cancer. https://doi.org/10.1002/ijc.70679
Vancouver
Incorvaia L, Santini D, Matrana MR, Maruzzo M, Kopp RM, Antonuzzo L, et al. Global Real‐World Outcomes of Olaparib in Metastatic Castration‐Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations. International Journal of Cancer. 2026. doi:10.1002/ijc.70679
BibTeX
@article{Incorvaia2026,
author = {Incorvaia, Lorena and Santini, Daniele and Matrana, Marc R and Maruzzo, Marco and Kopp, Ray Manneh and Antonuzzo, Lorenzo and Bracarda, Sergio and Tural, Deniz and Procopio, Giuseppe and Bourlon, Maria T and Caffo, Orazio and Zapata Laguado, Martin Ignacio and Di Maio, Massimo and Maiorano, Brigida Anna and Conteduca, Vincenza and Rossetti, Sabrina and Lipari, Helga and Büttner, Thomas and Rizzo, Mimma and Ürün, Yüksel and Messina, Carlo and Marques Monteiro, Fernando Sabino and Soares, Andrey and Puglisi, Mattia and Principi, Alice and Lai, Eleonora and Mammone, Giulia and Stellato, Marco and Depetris, Ilaria and Bazan Russo, Tancredi Didier and Spricido, Isadora Yasbick and Gismondi, Camila Bobato Lara and Massari, Francesco and Pavan, Nicola and Santoni, Matteo and Taha, Tarek},
title = {Global Real‐World Outcomes of Olaparib in Metastatic Castration‐Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70679}
}
EUVIMED